DIPEPTIDYL PEPTIDASE-4 INHIBITORS, A NEW OPTION FOR THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS

  • Oana Albai
  • Bogdan Timar
  • Laura Diaconu
  • Romulus Timar
Keywords: dipeptidyl peptidase-4 inhibitors, sitagliptin, type 2 diabetes mellitus

Abstract

Objective: Despite the diversity of antidiabetic medication currently available, less than half of the patients with type 2 diabetes meet the therapeutic targets recommended by the guidelines: HbA1c <7%, or even <6.5%. This study aimed to investigate the efficacy and safety of sitagliptin in patients with type 2 diabetes mellitus, with inadequate glycemic control, as well as the effects on cardiovascular risk factors. Material and method: The study included 348 patients, 161 men (46.3%) and 187 women (53.7%), with mean age of 56.1 ± 6.2 years, who started treatment with sitagliptin, combined with either metformin, sulphonylurea or both. Results and discussions: Sitagliptin improved glycemic control reducing average HbA1c with 1.1%; the average weight decreased with 1.7 kg after 24 weeks of treatment, and the lipid profile improved significantly. Conclusions: Sitagliptin offers a new therapeutic option in patients with type 2 diabetes mellitus, with the advantage of a single dose oral administration.

Published
2012-12-15
How to Cite
Albai, Oana, Bogdan Timar, Laura Diaconu, and Romulus Timar. 2012. “DIPEPTIDYL PEPTIDASE-4 INHIBITORS, A NEW OPTION FOR THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS”. Romanian Journal of Diabetes Nutrition and Metabolic Diseases 19 (4), 343-51. https://rjdnmd.org/index.php/RJDNMD/article/view/251.
Section
Original Research Articles